Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 17/20 | 0.57 |
| ▸ | THRB | P10828 | 17/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29901375 | 1.00 | THRA (0.57) | THRATHRBBCHEACHEESR1 | |
| SCHEMBL23409584 | 0.93 | THRA (0.56) | THRATHRBBCHEACHE | |
| SCHEMBL29901415 | 0.93 | THRA (0.56) | THRATHRBBCHEACHE | |
| SCHEMBL29901378 | 0.92 | THRB (0.55) | THRATHRBBCHEACHEESR1 | |
| SCHEMBL23409426 | 0.92 | THRB (0.55) | THRATHRBBCHEACHEESR1 | |
| SCHEMBL23409586 | 0.90 | THRB (0.71) | THRATHRB | |
| SCHEMBL29971165 | 0.90 | THRB (0.71) | THRATHRB | |
| SCHEMBL23409612 | 0.89 | THRB (0.56) | THRATHRBBCHEACHEESR1 | |
| SCHEMBL23409501 | 0.89 | THRA (0.52) | THRATHRBBCHEACHEESR1 | |
| SCHEMBL29901451 | 0.89 | THRA (0.52) | THRATHRBBCHEACHEESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466781-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2022236133-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | AUTOBAHN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048992-A1 | NOVEL THYROMIMETICS | TSHR, TPO, CHRM1 | THRA 8/4885THRB 9/4885BCHE 534/4885 |
| US-12466781-B2 | Thyromimetics | TPO, TSHR, CHRM1 | THRA 6/4885THRB 9/4885BCHE 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.